The company's perilous state is reflected in its valuation, which now stands at just CHF7.91 million.

ThromboGenics is one of a clutch of Belgian biotech firms presenting at KBC Securities Healthcare Conference in the Belgian capital.

The SXI Life Sciences index, which comprises large- and midcap life science stocks, was off 0.52 percent.

The SXI Life Sciences index, which comprises large- and midcap life science stocks, was off 0.52 percent.

ThromboGenics is one of a clutch of Belgian biotech firms presenting at KBC Securities Healthcare Conference in the Belgian capital.

handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)

Roche Holding AG, of Basel, Switzerland, has also pledged to provide access to patient-level data, following widespread criticism of its lack of disclosure of data on its flu drug Tamiflu (oseltamivir phosphate).

handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)

By Cormac Sheridan Staff Writer Without revealing much in the way of new data, TopoTarget A/S enjoyed a 45 percent bounce in its share price during early trading Tuesday, as an analysis of the final top-line results from a registration trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) confirmed the drug exceeded the efficacy level defined by the study's primary endpoint, a minimum objective response rate (ORR) of 20 percent

The stock closed at DKK2.45, up 32.4 percent on Monday's close.

The stock closed at DKK2.45, up 32.4 percent.

By Cormac Sheridan Staff Writer DUBLIN, Ireland – Shares in Elan Corp

It is debatable whether any of those research centres are configured to participate in any IMI consortia.

Shares in the company (Frankfurt:VSC) gained 5 cents to close at €2.42 Tuesday.

Shares in the company (Frankfurt:VSC) gained 5 cents to close at €2.42 Tuesday.

The stock (NASDAQ:GENT) plunged more than 40 percent to a low of $6.96 after the news broke last Thursday, but it slowly creeped up to close at $8.88 on Monday.

If I was a shareholder of Elan, I would want that cash now and then Royalty Pharma can do what they want with it," Turner noted.

If I was a shareholder of Elan, I would want that cash now and then Royalty Pharma can do what they want with it," Turner noted.

The stock (NASDAQ:GENT) plunged more than 40 percent to a low of $6.96 after the news broke last Thursday, but it clawed back some of those losses to end the day at $9.61, a gain of 14 cents.